Corneal & External Eye Disease | Singapore National Eye Centre

Education

The Corneal and External Eye Disease Department is at the forefront of clinical innovations, application and education in the field of cornea transplantation.

Education and training opportunities are available to cornea sub-specialists on advanced transplantation techniques.

Two popular instructional courses conducted by the department (in collaboration with the Asia Cornea Society) have educated many cornea surgeons in the advanced techniques of Anterior Lamellar Keratoplasty (ALK) and Descemet-Stripping Automated Endothelial Keratoplasty (DSAEK).

Our cornea specialists also conduct international, regional and local teaching courses on advanced cornea transplantation techniques, refractive surgery, and pterygium surgery at various overseas ophthalmological meetings of international standing such as the American Academy of Ophthalmology. We have further shared our experiences by contributing to various publications and book chapters on all aspects of cornea diseases and management.

The Cornea Department offers comprehensive Cornea Fellowships for ophthalmologists to be future cornea sub-specialists. The SNEC Cornea Fellowship is competitive in nature and process and is merit-based. International Fellows from the United Kingdom, Netherlands, Mexico, China, Thailand, India and the Philippines have benefitted from the training at the SNEC Cornea Department. They are:

Name	Country
Dr Jan Van der Hoek	United Kingdom
Dr Cesar Gomezperalta	Mexico
Dr Federico Luengo	Argentina
Dr Michele Sala	Italy
Dr Rania A I Shibayeh	Jordan
Dr Mohamed Moustafa	Egypt
Dr Apiwat Pothikumjohn	Thailand
Dr Anna Lisa Yu	Philippines
Dr Jessica Abano	Philippines
Dr Howard Yu Cajucom-Uy	Philippines
Dr Made Susiyanti	Indonesia
Dr Vanathi Murgesan	India
Dr Kamble Pramod Changdeo	India
Dr Anand Parthasarathy	India
Dr Andrea Liu	China
Dr Wei Rui Hua	China
Dr Recce Hall	New Zealand
Dr Karim Mohamed Noriega	Mexico
Dr Romesh Angunawela	United Kingdom

Our Care Team

Back to Clinical Interests

Our Care Team

News

Research Formosa Pharmaceuticals and SERI Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases SINGAPORE / TAIPEI — April 30, 2026 – Formosa Pharmaceuticals, Inc. (“Formosa”, 6838.TW) and the Singapore Eye Research Institute (“SERI”) are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage Formosa’s proprietary APNT® (Active Pharmaceutical (ingredient) Nanoparticle Technology) and SERI’s world-class clinical research expertise, led by renowned Clinician Scientist, Associate Professor Yu-Chi Liu, MD, PhD. The collaboration aims to address significant unmet needs in the treatment of corneal and ocular surface diseases. By combining innovative and clinically validated drug delivery platforms with deep clinical insights, the joint effort seeks to enhance the efficacy, bioavailability, and safety of topical ocular therapies, bringing new therapies to clinical practice. Synergy of Innovation and Clinical Excellence A/Prof Yu-Chi Liu, clinician scientist at Singapore National Eye Center and Principal Investigator at SERI, brings extensive experience in corneal neuropathy and translational medicine to the collaboration. Her recent work in diabetic keratopathy and ocular surface inflammation will be pivotal in guiding the development of formulations targeting complex anterior segment conditions. "Collaborating with Formosa Pharmaceuticals allows us to bridge the gap between benchside innovation and bedside application," said A/Prof. Yu-Chi Liu. "Our goal is to utilize advanced formulation technologies like APNT to create treatments that are not only more effective but also less burdensome for patients suffering from ocular conditions." Leveraging APNT® Technology Formosa Pharmaceuticals’ APNT® platform specializes in reducing the particle size of active pharmaceutical ingredients (APIs) to stable, uniform nanoparticles. This technology is a hallmark of Formosa's development pipeline, offering a powerful solution for improving the delivery of poorly soluble drugs to the target tissues and organs. "We are honored to work alongside Professor Liu and her distinguished team at SERI," said Erick Co, President & CEO of Formosa Pharmaceuticals. "Initial efforts have confirmed compatibility of APNT and SERI’s research models and prompt us to extend our partnership. SERI’s reputation for excellence in vision research, backed by their comprehensive capabilities and facilities, are unparalleled. Together, we are excited to translate the research findings into better clinical outcomes."

30 Apr 2026 Read Story

Education Singapore National Eye Centre and Singapore Polytechnic collaborate to strengthen optometrists’ role in community eye care The partnership will see both parties co-develop the Clinical Decision-Making in Community Optometry training programme for practicing community optometrists to build on their competencies to deliver quality eye care in the community.

05 Mar 2026 Read Story

Announcements Singapore Eye Research Institute tops ScholarGPS rankings in Ophthalmology The Institute has placed #1 in ophthalmology among all non-academic institutes, and #2 in the same field among all institutes, globally.

28 Jan 2026 Read Story

View All